Member Info for Livedataaccount

Did you challenge Dr Smith on the value curve?

Too much change at Avacta

Unlikely, Timster

Not sure about that. I think many are waiting for clarification on Alan's commercial strategy.

Is it realistic avacta will get AVA3996 into the clinic this year? I had thought the Ind filing would be done by now.

Avacta said 'AVA3996 is in pre-clinical development with the aim of submitting an Investigational New Drug (IND) application to allow clinical development to begin during 2024.'

Avacta borrow ~50m

Spend a chunk of it on 2 dx Companies

Months later sell the dx companies

Cant see it myself

Avacta's RNS says quite the opposite?

From the Avacta RNS.

'Therefore, in parallel with the completion of cohort 7, the Company intends to begin a short study to explore more frequent dosing (fortnightly) of AVA6000 as a first line treatment in patients with soft tissue sarcoma. The study is expected to begin in Q4 2023 subject to receipt of approval of a protocol amendment from the US Food & Drug Administration (FDA) '

From the Avacta RNS.

'Therefore, in parallel with the completion of cohort 7, the Company intends to begin a short study to explore more frequent dosing (fortnightly) of AVA6000 as a first line treatment in patients with soft tissue sarcoma. The study is expected to begin in Q4 2023 subject to receipt of approval of a protocol amendment from the US Food & Drug Administration (FDA) '

Can't wait for it, Tinster!

This circle will carry on until new financing is arranged.

It's in heights interests

I still find the use of the fund raise to buy the diagnostics companies eyebrow raising considering the market is quite obviously jittery (judging by the share price) about Avacta's cash position and funding going forward and the main asset of the company is the Tx division. Can only assume Avacta's board have it all sorted.

That's a very good point.

Head of r and d lives in America

Chris would make an excellent future CEO

Well done Avacta for hiring Chris Coughlin. She was brilliant presenting the 1a update. Brought a feel of a blue chip company to Avacta.

This is a very good hire.

Good, honest post, JES.

Can't see that helping the value curve and you likely the get some abuse from the Avacta die hards.

Unlikely Avacta will release significant news tomorrow being Friday, so look to next week for the value curve rise. It's currently 30% down from when the CEO stated Avacta are at the start.

I would hope the new chief business officer is now in talks with various companies. Surely it will take months for a bio pharma deal though.

The share price is now down circa 35 percent since the 1a progress presentation only weeks ago.

Come on Alan, what's going on!

Is it likely to affect the value curve, Sujood?

Curve looks to be turning upwards!